Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

ALNYLAM PHARMACEUTICALS, INC. (ALNY)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/17/2018 09/18/2018 09/19/2018 09/20/2018 09/21/2018 Date
93.35(c) 93.75(c) 94.82(c) 95.21(c) 94.57(c) Last
706 051 552 675 518 150 523 139 735 739 Volume
-3.90% +0.43% +1.14% +0.41% -0.67% Change
More quotes
Financials (USD)
Sales 2018 103 M
EBIT 2018 -754 M
Net income 2018 -719 M
Finance 2018 653 M
Yield 2018 -
Sales 2019 215 M
EBIT 2019 -764 M
Net income 2019 -746 M
Finance 2019 372 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 86,1x
EV / Sales2019 42,6x
Capitalization 9 520 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
09/22ALNYLAM PHARMACEUTICALS : Dr. Jared Gollob Joins Kymera Therapeutics as Chief Me..
AQ
09/20ALNYLAM Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceedi..
PR
09/19ALNYLAM PHARMACEUTICALS, INC. : Pomerantz Law Firm Investigates Claims On Behalf..
AC
09/18ALNYLAM PHARMACEUTICALS : Announces Publication in Circulation of Exploratory Ca..
AQ
09/14ALNYLAM PHARMACEUTICALS : Announces Publication in Circulation of Exploratory Ca..
BU
09/14ICER PANEL : hATTR treatments have low value
AQ
09/13ALNYLAM INVESTIGATION : Bernstein Liebhard LLP Announces Investigation Of Alnyla..
PR
09/12Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Phar..
PR
09/12Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmac..
PR
09/12MANAGEMENT TRACKS : Cheng joins Akero, bluebird COO leaving
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/17Alnylam Pharmaceuticals’ $ALNY “Buy” Rating Reaffirmed at Needham & Compa.. 
09/16Alnylam Pharmaceuticals, Inc. $ALNY Expected to Announce Earnings of -$1.82 P.. 
09/14Alnylam announces publication of data showing effect of patisiran on cardiac .. 
09/14Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc.. 
09/13Alnylam selloff continues, shares fail to hold earlier gain
1
More tweets
Qtime:66
News from SeekingAlpha
09/18YOUR DAILY PHARMA SCOOP : Alnylam Regains, Karyopharm Positive, Teva Approved 
09/14Alnylam announces publication of data showing effect of patisiran on cardiac .. 
09/13Alnylam selloff continues, shares fail to hold earlier gain 
09/11Alnylam Pharmaceuticals (ALNY) ONPATTRO And Investigational ALN-TTRsc02 For T.. 
09/06ALNYLAM : Analysts See A Comet On The Rise 
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, I
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 144 $
Spread / Average Target 53%
EPS Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne L. Greenstreet Chief Operating Officer & Executive Vice President
Manmeet Singh Soni Chief Financial Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.-25.56%9 520
CELLTRION, INC.--.--%33 388
IQVIA HOLDINGS INC30.32%25 763
LONZA GROUP18.80%24 291
INCYTE CORPORATION-29.69%14 156
SEATTLE GENETICS, INC.45.35%12 348